Advertisement

Advertisement
Dean Fennell, FRCP, PhD, on Mesothelioma: Nivolumab vs Placebo in Relapsed Disease

Dean Fennell, FRCP, PhD, on Mesothelioma: Nivolumab vs Placebo in Relapsed Disease

Incidence of Brain Metastases in Patients Diagnosed With Stage IV NSCLC During the COVID-19 Pandemic

Computed tomography and/or magnetic resonance imaging demonstrated that 39% of patients diagnosed with stage IV non–small cell lung cancer (NSCLC) presented with de novo brain metastases during the COVID-19 pandemic. This percentage was higher than the historic rate of 25%, and many of these patients were asymptomatic for brain metastases. These findings were presented by Cui et al at the European Lung Cancer Virtual Congress 2021.

Some Patients With Lung Cancer Report Feeling Uninformed About Their Disease, Uninvolved With Their Treatment

More than 1 in 10 patients with lung cancer do not know what type of tumor they have, according to data from a 17-country study carried out by the Global Lung Cancer Coalition and presented by Beattie et al at the European Lung Cancer Virtual Congress 2021. Nearly one in five patients surveyed also reported that they did not feel involved in decisions about their treatment and care, and a similar proportion felt that they had never or only sometimes been treated with dignity and respect by those treating them.

Adagrasib for Patients With Advanced KRAS G12C–Mutated NSCLC

Adagrasib for Patients With Advanced <em>KRAS</em> G12C–Mutated NSCLC

Treatment with the KRAS G12C inhibitor adagrasib showed clinical activity in patients with advanced non–small cell lung cancer (NSCLC) harboring a KRAS G12C mutation, confirming its role as a therapeutic target. Results from the KRYSTAL-1 trial were reported at the European Lung Cancer Virtual Congress 2021 by Gregory J. Riely, MD, PhD.

ASCO Publishes Guideline Endorsement of ASTRO Guideline for Radiation Therapy in SCLC

An ASCO Expert Panel has endorsed an American Society for Radiation Oncology (ASTRO) guideline on radiation therapy for small cell lung cancer (SCLC), stating the recommendations in the ASTRO guideline “are clear, thorough, and based upon the most relevant scientific evidence” available.1

Immunotherapy Doublet as Maintenance Therapy for Extensive-Disease SCLC

Immunotherapy Doublet as Maintenance Therapy for Extensive-Disease SCLC

As reported in the Journal of Clinical Oncology by Taofeek K. Owonikoko, MD, PhD, and colleagues, the phase III CheckMate 451 trial showed no improvement in overall survival with combined nivolumab and ipilimumab vs placebo as maintenance therapy for extensive-disease small cell lung cancer.

Advertisement


Advertisement